AAR2

Across TCGA pan-cancer cohorts, AAR2 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated AAR2 data layer compared with 27 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher AAR2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated AAR2 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LUAD show a favorable association.

CCRCC, OV, and PDAC are the cancer types where AAR2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	All	0.668	1.000	.001	62	view →
OV	DFS	Quartile	All	0.535	0.950	.011	12	view →
PDAC	OS	Tertile	III,IV	0.277	0.743	.030	12	view →
UCEC	DFS	Quartile	All	0.702	1.000	.001	10	view →
HNSC	OS	Tertile	III,IV	1.000	0.923	.042	9	view →
LUAD	OS	Median	All	0.999	0.923	.016	6	view →
GBM	OS	Median	All	0.514	0.304	.025	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

AAR2–CCRCC (DFS)

Open the CCRCC breakdown →